AC Immune SA develops precision therapeutics and diagnostics for neurodegenerative diseases driven by misfolded proteins. The clinical-stage biopharmaceutical company uses its SupraAntigen® and Morphomer® platforms to advance active immunotherapies, small molecules, antibodies, vaccines and diagnostic programs for Alzheimer’s disease, Parkinson’s disease and NeuroOrphan indications.
Company news commonly covers clinical updates for ACI-24 in the ABATE Alzheimer’s disease study, ACI-7104.056 in the VacSYn Parkinson’s disease trial, ACI-19764 as an NLRP3 inflammasome inhibitor, and Tau Morphomer® small-molecule programs. Updates also include collaboration activity with global pharmaceutical partners, milestone payments, symposium presentations, financial results and cash runway disclosures.
The clinical-stage biopharmaceutical company AC Immune (NASDAQ: ACIU) announced its participation in the Jefferies 2024 Global Healthcare Conference in New York, scheduled for June 5-6, 2024.
Company management will engage in a fireside chat on June 5 at 3:30 PM (ET), which can be accessed via webcast. Additionally, AC Immune will hold one-on-one meetings with investors. This involvement aims to highlight their precision medicine advancements for neurodegenerative diseases.
The webcast and an archived replay will be available on AC Immune’s website.
AC Immune reported its first quarter 2024 financial results and corporate update, highlighting a landmark deal with Takeda for ACI-24.060 with $100 million upfront and potential payments of up to $2.1 billion. The ACI-24.060 ABATE Phase 2 trial is on track to report results in Q2 2024, and the ACI-7104.056 VacSYn Phase 2 trial in Parkinson's disease is progressing. The company has a three-year cash runway with CHF 104.8 million. Financially, the company had a cash balance of CHF 104.8 million, R&D expenses of CHF 15.2 million, and reported a net loss of CHF 17.9 million for the quarter.
AC Immune and Takeda have signed an exclusive option and license agreement for ACI-24.060, an active immunotherapy targeting Amyloid Beta for Alzheimer's disease. Takeda will pay AC Immune $100 million upfront, with additional potential milestones totaling around $2.1 billion. AC Immune will host a conference call and webcast to discuss the agreement.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.